Cargando…

Neoadjuvant Immunotherapy: A Promising New Standard of Care

Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various malignancies, with preclinical studies showing improved immune responses in the preoperative setting. FDA-approved neoadjuvant-immunotherapy-based approaches include triple-negative breast cancer and early non-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boydell, Emma, Sandoval, Jose L., Michielin, Olivier, Obeid, Michel, Addeo, Alfredo, Friedlaender, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380420/ https://www.ncbi.nlm.nih.gov/pubmed/37511609 http://dx.doi.org/10.3390/ijms241411849

Ejemplares similares

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

COVID-19 and lung cancer: risks, mechanisms and treatment interactions
por: Addeo, Alfredo, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

A New Generation of Vaccines in the Age of Immunotherapy
por: Addeo, Alfredo, et al.
Publicado: (2021)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

VISTA: A Promising Target for Cancer Immunotherapy?
por: Tagliamento, Marco, et al.
Publicado: (2021)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy
por: Banna, Giuseppe Luigi, et al.
Publicado: (2019)

Tracking the tail
por: Friedlaender, Alex, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
por: Mederos, Nuria, et al.
Publicado: (2020)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature Review
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
por: Friedlaender, Alex, et al.
Publicado: (2019)

Cellular Therapy in NSCLC: Between Myth and Reality
por: Imbimbo, Martina, et al.
Publicado: (2023)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Cancer and COVID-19: Unmasking their ties
por: Addeo, A., et al.
Publicado: (2020)

Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022)

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
por: Ghosn, Jaqueline, et al.
Publicado: (2018)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
por: Raggi, Daniele, et al.
Publicado: (2021)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

1393P Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy
por: Banna, G.L., et al.
Publicado: (2020)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
por: Mancini, Patrizia, et al.
Publicado: (2014)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i4ept40bad5c4fabp65cu1m1oo